Gain Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Gain Therapeutics şirketinin toplam hissedar öz sermayesi $11.8M ve toplam borcu $486.4K olup, bu da borç-öz sermaye oranını 4.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $19.2M ve $7.4M dir.

Anahtar bilgiler

4.1%

Borç/özkaynak oranı

US$486.40k

Borç

Faiz karşılama oranı	n/a
Nakit	US$16.94m
Eşitlik	US$11.78m
Toplam yükümlülükler	US$7.41m
Toplam varlıklar	US$19.20m

Son finansal sağlık güncellemeleri

Recent updates

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

May 29

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential

Jan 12

Gain Therapeutics appoints CEO

Sep 20

Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value

Oct 27

Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing

Aug 19

Gain Therapeutics EPS misses by $0.29

May 10

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: GANX 'nin kısa vadeli varlıkları ( $18.5M ) kısa vadeli yükümlülüklerini ( $6.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: GANX şirketinin kısa vadeli varlıkları ( $18.5M ) uzun vadeli yükümlülüklerini ( $888.5K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: GANX şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: GANX şirketinin 5 yıl önce negatif özkaynağı vardı, ancak şu anda pozitif ve dolayısıyla iyileşme kaydetti.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: GANX son raporlanan serbest nakit akışına göre 11 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: GANX serbest nakit akışı tahminlerine göre 10 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Gain Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Gain Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq Regarding MVLS Deficiency

Gain Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq Regarding MVLS Deficiency

Recent updates

Gain Therapeutics, Inc. Announces Presentation of Preclinical Data for the Product Candidate, GT-02287

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Gain Therapeutics, Inc. Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287

Gain Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq Regarding MVLS Deficiency

Gain Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq Regarding MVLS Deficiency

Gain Therapeutics, Inc. Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease

Gain Therapeutics, Inc. Announces CEO Changes

Gain Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $10.999898 million.

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

Consensus EPS estimates upgraded to US$0.97 loss, revenue downgraded

Gain Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Consensus revenue estimates fall by 40%

Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287

Gain Therapeutics, Inc. Appoints Gene Mack as Chief Financial Officer

Independent Director recently bought US$116k worth of stock

Gain Therapeutics, Inc. Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

New major risk - Financial position

Gain Therapeutics, Inc. Announces Xavi Barril Leaves as Chief Technology Officer

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential

Consensus revenue estimates decrease by 11%, EPS upgraded

Gain Therapeutics, Inc. Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

Gain Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $6.65573 million.

Gain Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $6.65573 million.

Gain Therapeutics, Inc. has filed a Follow-on Equity Offering.

Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

Gain Therapeutics Presents New Preclinical Data Demonstrating A Reduction of Plasma Neurodegeneration Biomarker NfL After Administration of Its Drug Candidate GT-02287 in GBA1 Parkinson's Disease Model

Consensus revenue estimates fall by 16%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.62 loss per share (vs US$0.43 loss in 2Q 2022)

Consensus revenue estimates increase by 193%, EPS downgraded

Consensus revenue estimates increase by 17%

Gain Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 24%

High number of new and inexperienced directors

Gain Therapeutics, Inc. Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson's Disease Patient-Derived Dopaminergic Neurons

Gain Therapeutics Announces Chief Executive Officer Changes

Gain Therapeutics appoints CEO

Gain Therapeutics, Inc. Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of Its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson's Disease

Price target decreased to US$19.25

Consensus forecasts updated

Consensus forecasts updated

Gain Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

Price target decreased to US$22.00

High number of new and inexperienced directors

Price target decreased to US$22.00

Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid

Gain Therapeutics Presents Preclinical Data on Its Structurally Targeted Allosteric Regulators in Gba1 Gaucher Disease At the Worldsymposium 2022

Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value

Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-Derived Ipsc Study Evaluating Star Compounds as A Treatment for Gaucher and Parkinson’S Disease

Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing

Gain Therapeutics EPS misses by $0.29

Gain Therapeutics, Inc. Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related a-synucleopathies at the XXVI IAPRD World Congress

Gain Therapeutics, Inc. has completed an IPO in the amount of $40.000004 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin